Pharmacokinetics of flunixin in mature heifers following multiple intravenous administration

• Autorzy: Jaroszewski J. , Jedziniak P. , Markiewicz W. , Grabowski T. , Chrostowska M. , Szprengier-Juszkiewicz T.
• Języki publikacji: EN

Abstrakty

EN

The pharmacokinetics of flunixin meglumine was determined after its multiple (altogether 4 doses at 24-hours intervals) intravenous administration at a dose of 2.2 mg/kg body weight in six mature clinically healthy heifers. Plasma flunixin and its metabolite 5-hydroxyflunixin concentrations were analyzed with high-pressure liquid chromatography using an assay with a lower limit detection of 0.03 μg/ml for both substances. Plasma concentrations versus time curves were described by a two compartment open model. Mean plasma flunixin concentrations were similar on day 1 and 4, and than rapidly decreased (within 2 hours) from initial concentrations higher than 10 μg/ml to the concentrations lower than 1 μg/ml. The distribution phase of flunixin was short (t05α = 0.29 ± 0.16 and 0.18 ± 0.04 on day 1 and 4, respectively) and the elimination phase was more prolonged (t05ß = 3.30 + 0.60 and 3.26 + 0.22 on day 1 and 4, respectively). The mean residence time of flunixin was similar on day 1 (1.83 ± 0.83) and 4 (1.88 + 0.46), and for 5-hydroxyflunixin this parameter was insignificantly (P > 0.05) higher on day 1 (5.49 ± 2.22) as compared to that found on day 4 (3.99 ± 2.17). The clearance of flunixin was similar on both examined days (0.23 ± 0.12 on day 1 and 0.31 ± 0.15 on day 4), and for 5-hydroxyflunixin was insignificantly (P > 0.05) lower on day 1 (2.37 ± 1.21) as compared to that determined on day 4 (3.23 ± 1.06). Our data indicate that multiple administration of flunixin did not alter significantly the parent drug and its metabolite concentrations in plasma, however may cause some small changes in pharmacokinetic parameters.

Słowa kluczowe

EN

flunixin meglumine; 5-hydroxyflunixin; pharmacokinetics; heifer; mature heifer; intravenous administration; healthy heifer

• Wydawca: -
• Czasopismo: Polish Journal of Veterinary Sciences
• Rocznik: 2008
• Tom: 11
• Numer: 3
• Opis fizyczny: p.199-203,fig.,ref.

Twórcy

autor

Jaroszewski J.

• University of Warmia and Mazury, 10-719 Olsztyn, Poland

autor

Jedziniak P.

autor

Markiewicz W.

autor

Grabowski T.

autor

Chrostowska M.

autor

Szprengier-Juszkiewicz T.

Bibliografia

• Anderson KL, Neff-Davis CA, Davis LE, Bass VD (1990) Pharmacokinetics of flunixin meglumine in lactating cattle after single and multiple intramuscular and intra­venous administrations. Am J Vet Res 51: 1464-1467.
• Cheng Z, McKeller Q, Nolan A (1998) Pharmacokinetic stu­dies of flunixin meglumine and phenylbutazone in plasma, exudate and transudate in sheep. J Vet Pharma­col Ther 21: 315-321.
• Dascanio JJ, Mechor GD, Grohn YT, Kenney DG, Booker CA, Thompson P, Chiffelle CL, Musser JM, Warnick LD (1995) Effect of phenylbutazone and flunixin meglumine on acute toxic mastitis in dairy cows. Am J Vet Res 56: 1213-1308.
• Friton GM, Cajal C, Ramirez Romero R, Kleemann R (2004) Clinical efficacy of meloxicam (Metacam) and flunixin (Finadyne) as adjuncts to antibacterial treatment of respiratory disease in fattening cattle. Berl Munch Tierarztl Wochenschr 117: 304-309.
• Gibaldi M, Perrier M (1982) Pharmacokinetics. 2nd ed., Re­vised and expanded, Marcel Dekker, Inc.
• Jedziniak P, Szprengier-Juszkiewicz T, Olejnik M, Jaros­zewski J (2007) Determination of flunixin and 5-hy- droxyflunixin in bovine plasma with HPLC-UV-method development, validation and verification. Bull Vet Inst Puławy 51: 261-266.
• Konigsson K, Torneke K, Engeland IV, Odensvik K, Kindahl H (2003) Pharmacokinetics and pharmacodynamic ef­fects of flunixin after intravenous, intramuscular and oral administration to dairy goats. Acta Vet Scand 44: 153-159.
• Landoni MF, Cunningham FM, Lees P (1995) Determina­tion of pharmacokinetics and pharmacodynamics of flunixin in calves by use of pharmacokinetic/phar- macodynamic modeling. Am J Vet Res 56: 786-794.
• Navarre CB, Ravis WR, Nagilla R, Deshmukh D, Simpkins A, Duran SH, Pugh DG (2001) Pharmacokinetics of flunixin meglumine in llamas following a single intra­venous dose. J Vet Pharmacol Ther 24: 361-364.
• Odensvik K (1995) Pharmacokinetics of flunixin and its ef­fect on prostaglandin F2 alpha metabolite concentrations after oral and intravenous administration in heifers. J Vet Pharmacol Ther 18: 254-259.
• Odensvik K, Johansson IM. (1995) High-performance liquid chromatography method for determination of flunixin in bovine plasma and pharmacokinetics after single and re­peated doses of the drug. Am J Vet Res 56: 489-495.
• Odensvik K, Magnusson U (1996) Effect of oral administra­tion of flunixin meglumine on the inflammatory response to endotoxin in heifers. Am J Vet Res 57: 201-204.
• Oukessou M (1994) Kinetic disposition of flunixin meg­lumine in the camel (Camelus dromedarius) Vet Res 25: 71-75.
• Rantala M, Kaartinen L, Valimaki E, Stryrman M, Hiek- karanta M, Niemi A, Saari L, Pyorala S (2002) Efficacy and pharmacokinetics of enrofloxacin and flunixin meg­lumine for treatment of cows with experimentally in­duced Escherichia coli mastitis. J Vet Pharmacol Ther 25: 251-258.
• Riviere JE (1999) Comparative Pharmacokinetics: Prin­ciples, Techniques, and Applications, 1st ed., Iowa State University Press, Ames.
• Rowland M, Tozer TN (1989) Clinical Pharmacokinetics: Concepts and Applications. 2nd ed., Lea & Febiger.
• Vane JR, Botting RM (1995) New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 44: 1-10.
• Wasfi IA, Boni NS, Abdel Hadi A, Elghazali M, Zorob O, Alkatheeri NA, Barezaiq IM (1998) Pharmacokinetics, metabolism and urinary detection time of flunixin after intravenous administration in camels. J Vet Pharmacol Ther 21: 203-208.
• Welsh EM, McKellar QA, Nolan AM (1993) The phar­macokinetics of flunixin meglumine in the sheep. J Vet Pharmacol Ther 16: 181-188.
• Weiss M (1981) Residence time and accumulation of drugs in the body. Int J Clin Pharmacol Ther Toxicol 19: 82-85.
• Weiss M (1984) Model-independent assessment of accumu­lation kinetics based on moments of drug disposition curves. Eur J Clin Pharmacol 27: 355-359.